著者

王 子灃 譚 成博 川堀 真人 七戸 秀夫 寶金 清博

出版者

北海道医学会

雑誌

北海道医学雑誌 (ISSN:03676102)

巻号頁・発行日

vol.93, no.1, pp.13-20, 2018-05-01

---

A recent breakthrough in cell therapy is expected to reverse the neurological sequelae of stroke, spinal cord injury, traumatic brain injury and so forth. In fact, various clinical trials concerning cell therapy for central nervous system (CNS) disease have been reported all over the world. Although some pioneer studies were conducted in China, accurate information was not always conveyed to Japan due to the language barrier. In our present article, we reported our systematic review of the scientific papers and the protocols about clinical trials concerning cell therapy for CNS disease in China. Moreover, we reported the regulatory framework for the stem cell research in China. It is noteworthy that we referred to not only English-based databases, but also Chinese-based databases. In conclusion, though some problems remain in China, we expect the acceleration of cell therapy for CNS disease in the future because of the new regulatory framework.